{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"13"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"20"}],"units":"Participants"}],"description":"The complete response (CR) and very good partial response (VgPR) rate in patients undergoing ASCT using thalidomide, bortezomib and melphalan","groups":[{"description":"Phase I - Thalidomide Dose Level 600 mg","id":"OG000","title":"Phase I - Thalidomide Dose Level 600 mg"},{"description":"Phase I - Thalidomide Dose Level 800 mg","id":"OG001","title":"Phase I - Thalidomide Dose Level 800 mg"},{"description":"Phase I - Thalidomide Dose Level 1000 mg","id":"OG002","title":"Phase I - Thalidomide Dose Level 1000 mg"},{"description":"Phase 2 Thalidomide Dose Level 1000 mg","id":"OG003","title":"Phase 2"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Assessments will be made from Day +28 after transplantation for 3 months and then at 3 month intervals until demonstration of disease progression and initiation of further therapy, an average of 9 months","title":"Complete Response (CR) and Very Good Partial Response (VgPR) Rate","type":"SECONDARY","unitOfMeasure":"Participants"}